EOS imaging has acquired the rights to an exclusive, worldwide license for a technology dedicated to the prognosis of adolescent scoliosis using 3D and 2D clinical parameters obtained from EOS systems.
A multicentre clinical study has launched in eight centres equipped with EOS systems (in the USA, Canada, France, Japan, Singapore and Hong Kong) to measure the technology’s ability to predict the risk of young patients with mild scoliosis later developing a severe deformity.
Marie Meynadier, chief executive officer says: “This promising technology confirms the value of the 3D data naturally associated with EOS images in developing applications and services dedicated to orthopaedic care pathways. Acquiring these exclusive rights is an integral part of our global strategy to offer doctors not only cutting-edge imaging technology, but also a full suite of software and services to help them in their therapeutic strategies and execution, to the greatest benefit to patients.”
This software’s algorithm, developed by Montreal-based surgeons and engineers, uses several clinical parameters available in patient reports from the sterEOS workstation. It establishes a predictive score, which could measure the risk of a patient at an early, mild stage of scoliosis developing a severe form of the pathology. Preliminary data on this predictive score will be presented at the forthcoming 50th Scoliosis Research Society Meeting (30 September–3 October, Minneapolis, USA).
